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Recent genome-wide analyses have detected numerous cancer-speciﬁc alternative splicing (AS) events.
Whether transcripts containing cancer-speciﬁc AS events are likely to be translated into functional proteins
or simply reﬂect noisy splicing, thereby determining their clinical relevance, is not known. Here we show that
consistent with a noisy-splicing model, cancer-speciﬁc AS events generally tend to be rare, containing more
premature stop codons and have less identiﬁable functional domains in both the human and mouse.
Interestingly, common cancer-derived AS transcripts from tumour suppressor and oncogenes show
marked changes in premature stop-codon frequency; with tumour suppressor genes exhibiting increased
levels of premature stop codons whereas oncogenes have the opposite pattern. We conclude that tumours
tend to have faithful oncogene splicing and a higher incidence of premature stop codons among tumour
suppressor and cancer-speciﬁc splice variants showing the importance of considering splicing noise
when analysing cancer-speciﬁc splicing changes.
INTRODUCTION
Cancer cells are associated with profound changes at the
transcriptome level with hundreds of genes being up- or down-
regulated when compared with normal tissues (1). Transcrip-
tion proﬁling of cancer samples has led to an increased
understanding of cancer physiology and the identiﬁcation
of a number of transcriptional cancer markers. Alternative
splicing (AS) is a post-transcriptional process in eukaryotic
organisms by which multiple distinct functional transcripts
are produced from a single gene. It is now known that most
human genes undergo AS (2,3). Several studies have explored
cancer-related changes in AS patterns (reviewed in 4–7)
resulting in the identiﬁcation of an increasing number of
cancer-speciﬁc AS events in a variety of cancer tissues
(8–12). Given the high number of AS events unique to
cancer transcriptomes, cancer-speciﬁc transcripts have been
proposed to play a key role in cancer physiology (6,12).
Nevertheless, only a handful of cancer-speciﬁc AS events
have been experimentally validated (8,10). Given that a sig-
niﬁcant proportion of alternatively spliced transcripts result
from noisy splicing in normal human tissues (13–16), it is
possible that most cancer-speciﬁc AS results from aberrant
splicing in these abnormal cells and does not play any
signiﬁcant role in cancer onset or progression (6,9,11). Here,
by examining human and mouse expressed sequenced tags
(EST) libraries, we ask whether cancer transcriptomes show
any differences in transcript quality compared with normal
tissues.
RESULTS
Identiﬁcation of cancer-speciﬁc AS events in human
and mouse
A total of 10896 836 ESTs for the human and mouse were
downloaded from UniGene (17). Of these, 3 384 826 ESTs
had a clear disease state annotation and were split into 297
libraries representing normal 37 tissues and 362 cancer librar-
ies for 32 tissues for the human and 164 normal libraries
corresponding to 29 normal tissues and 42 cancer libraries
from 14 tissues for the mouse (Table 1). To identify AS
events, a complete exon template was constructed for each
gene by mapping all partial and full transcripts available
[using genomic mapping and alignment program (GMAP)
software (18)]. Known nested genes as well as orphan
exons, not present in any transcript extending beyond them,
were removed from further analysis. Individual ESTs were
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events. We identiﬁed a total of 1349 341 and 271 491 AS
transcripts containing AS events for the human and mouse,
respectively. Of these, a total of 1 259 641 (93.3%) and 199
943 (73.6%) for the human and mouse, respectively, were
found in both normal and cancer libraries, while 23 876
(1.8%) and 1956 (0.7%) were found only in cancer libraries.
The remainder 65 824 (4.9%) and 69 592 (25.6%) transcripts
were found to contain AS events exclusive to normal tissue-
derived libraries (Fig. 1). The higher percentage of normal-
speciﬁc AS events in mouse is explained by the limited
cancer transcripts available for this species (Table 1).
Cancer transcripts show signatures consistent
with splicing noise
We then assessed whether cancer libraries and in particular
cancer-speciﬁc transcripts show signatures consistent with
increased rates of splicing noise. If so, we expect cancer tran-
scripts to: (A) have a higher incidence of nonsense or frameshift
mutations which introduce a premature translation termination
codons to mRNAs resulting in truncated proteins or more often
rendering them vulnerable to nonsense-mediated decay (13,14).
In the case of cancer-speciﬁc transcripts, we can expect them
to: (B) have reduced identiﬁable functional components consist-
ent with higher rates of aberrant incorporation of non-coding
regions into the transcript (see Materials and Methods); (C) be
found mostly as single copy and (D) be present in only one
library thus not being part of the core cancer transcription
proﬁleasthesearemorelikelytoresultfromsplicingerrors(15).
Transcripts were classiﬁed according to whether they con-
tained AS events found in both normal and cancer tissues or
unique to either resulting in four groups: (1) normal common,
with transcripts containing AS events also found in at least one
cancer library; (2) normal-speciﬁc, whose AS events are only
found in normal tissue samples; (3) cancer common, containing
transcripts from cancer libraries with AS events also found in at
least one normal tissue library; and (4) cancer-speciﬁc with tran-
scripts with AS events unique to cancer libraries. Our results
show, compared with normal tissue-derived transcripts, an
increased incidence of premature stop codons among cancer-
derived transcripts which are higher for cancer-speciﬁc tran-
scripts (Fig. 2, P , 0.0001) in both the human and mouse. In
bothspecies,cancer-speciﬁceventswerealsofoundtohaveasig-
niﬁcantly lower number of identiﬁable functional components
(P , 0.0001;Fig. 3).Inaddition, wefoundthatthevastmajority
(79.0%) have been sequenced only once with 90.5% identiﬁed
inasingleESTlibraryinthehuman(Fig.4).Incontrast,normal-
speciﬁc transcripts show less-pronounced differences in
premature stop codons and functional components compared
with transcripts with normal-common AS events (Figs 2 and 3).
We also found that transcripts containing AS events particular
Figure 1. Schematic representation of the proportion of transcripts containing
AS events common in both normal and cancer libraries, or cancer/normal spe-
ciﬁc. First number in each label represents the total number of distinct AS
events detected and the second the number of genes represented for human
(Hs) and mouse (Mm).
Figure 2. Premature stop codons in normal and cancer AS events. Top panel
shows the percentage of premature stop codon containing AS events for
normal and cancer tissues subdivided into those containing AS events
unique to normal/cancer libraries or found in both. Bottom panel shows
average number of premature stop codons with events divided in the same
way as top panel. Stars represent signiﬁcant differences among groups from
top panels (Chi-square tests; P . 0.05 for all comparisons) and bottom
panels (Wilcoxon test; all signiﬁcant comparisons with P , 0.001 denoted
by ∗∗∗).
Table 1. Summary of transcripts from normal and cancer state
Species
name
Disease
state
Tissue
type
Development
stage
Library
count
EST
count
Human Normal 37 7 297 1687320
Cancer 34 5 362 920844
Mouse Normal 29 15 164 628506
Cancer 14 4 45 148156
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single copy or conﬁned to a single library (P ≤ 0.0001; Fig. 4).
Tumour suppressor and oncogenes reveal contrasting
transcript quality reductions in cancer libraries
Because tumour suppressor and oncogenes play a key role in
tumour progression, we tested whether these gene categories
presented any differences in the frequencies of disabled tran-
scripts. Inactivation of tumour suppressor genes NFI, FHIT
and TSG101 and strengthening oncogenes CD44 and RON
by AS have been reported (reviewed in 4,6). To test whether
splicing noise signatures affect tumour suppressor and onco-
genes differently, we divided all genes into oncogenes (648),
tumour suppressor (850) and other genes according to the Can-
cerGenes database (19). We found that even if as a whole
cancer-derived transcripts are more likely to contain premature
stop codons consistent with missplicing (Fig. 2), this increase
is not equally distributed between gene categories (Fig. 5).
Common cancer-derived oncogene transcripts show only mar-
ginal changes in the rate of premature stop codons compared
with transcripts derived from normal tissues (Fig. 5). In con-
trast, tumour suppressor genes show a marked increase in
the incidence of premature stop codons in cancer libraries
(Fig. 5, P , 0.001). These differences in transcript quality
among gene categories are not observed in normal libraries.
Analyses of transcripts speciﬁc to cancer or normal tissues
showed that cancer-speciﬁc AS events have an elevated rate
of premature stop codons in all three categories, further sug-
gesting that a signiﬁcant proportion of cancer-speciﬁc AS
events containing transcripts are likely to result from splicing
errors. We also found an elevated frequency in premature stop
codons among tumour suppressor-derived normal-speciﬁc AS
transcripts (Fig. 5; P ¼ 0.016 and P ¼ 0.014) which is not
explained by the fact that these genes have a slightly longer
average coding region (Supplementary Material, Figs S1 and
S2). When comparing transcript abundance in cancer-speciﬁc
AS events (Fig. 6), we found that oncogenes are more likely to
produce cancer-speciﬁc AS events with more than one copy
and to be found in more than one library than other genes
(P ¼ 0.037; Fig. 6). This pattern is not found for normal-
speciﬁc AS transcripts where the group of other genes were
far more likely to be present in multiple copies and
multiple libraries than both tumour suppressor and oncogenes
(P , 0.0001; Fig. 6).
In order to assess functional content, we examined the
distribution of functional components for oncogenes, tumour
suppressor and other genes in both cancer and normal AS tran-
scripts. For AS events found in both cancer and normal librar-
ies, oncogenes and tumour suppressor-derived transcripts had
higher frequencies of functional components compared with
other genes (Fig. 7, P ¼ 0.008 and P ¼ 0.04), suggesting
that AS areas contribute signiﬁcantly to the functional proper-
ties of these genes protein products. While among normal-
speciﬁc AS areas, there is a reduction in the functional
content from oncogenes, in cancer-speciﬁc AS areas it is
tumour suppressor genes which show a marked reduction in
functional content. No such reduction is observed among AS
areas of oncogenes (Fig. 7, P ¼ 0.019).
DISCUSSION
We have shown that transcripts derived from cancer libraries
have an elevated rate of stop codons consistent with increased
rates of missplicing in cancer transcriptomes. Transcripts with
alternatively splicing events unique to cancer libraries showed
an even greater enrichment in premature stop codons (Fig. 2)
as well as containing fewer identiﬁable functional domains
(Fig. 3). Importantly, all cancer-speciﬁc transcripts were
found in fewer than 10 cancer libraries (out of a total of
362) with almost 80% of them found as a single copy
(Fig. 4). These features suggest that a signiﬁcant proportion
of these transcripts are unlikely to produce a functional
protein product and given that no cancer-speciﬁc transcripts
were found to be ubiquitous to all cancer libraries or even a
cancer type, we believe that the majority of cancer-speciﬁc
transcripts, although probably functional, are unlikely to
Figure 3. Identiﬁable functional components in AS events in cancer and
normal tissues. Top panel shows the percentage of AS events with at least
one identiﬁable functional component (see Materials and Methods). Bottom
panel shows average number of identiﬁable functional components per AS
area. In both panels, transcripts were divided as in Figure 2. Stars represent
signiﬁcant differences among groups from top panels (Chi-square tests; P .
0.05 for all comparisons) and bottom panels (Wilcoxon tests; P , 0.001 for
all signiﬁcant comparisons denoted by ∗∗∗).
4424 Human Molecular Genetics, 2011, Vol. 20, No. 22Figure 4. Normal and cancer-speciﬁc AS events frequency distributions. Top panel shows the number of times each AS event is found and bottom panel shows
the number of libraries where an AS event is found. Error bars in distributions from normal-speciﬁc transcripts represent 100 randomly selected samples from
normal-speciﬁc transcripts of equal transcript and library number to the number of cancer-speciﬁc transcripts and libraries available.
Figure 5. Premature stop-codon frequency in oncogenes, tumour suppressor and other genes. Top panel shows the percentage of premature stop-codon contain-
ing AS events. Bottom panel shows the average number of stop codons per AS events. AS events were classiﬁed depending on whether they were derived from
oncogenes tumour suppressor and other genes. Broader groupings from Figure 2 and Figure 3 are also labelled. Stars represent signiﬁcant differences among
groups from top panels (Chi-square tests; no signiﬁcant differences found among groups with P , 0.05) and bottom panels (Wilcoxon test; signiﬁcant compar-
isons at 0.05 are denoted by ∗ and those with P , 0.001 are denoted by ∗∗∗).
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that the clinical and diagnostic relevance of particular
cancer-speciﬁc transcripts may prove rather limited.
In contrast, analyses of transcripts only found in normal
tissue samples did not reveal a similar increase in noise signa-
tures (Figs 2 and 3) and a signiﬁcantly greater proportion were
found in multiple libraries (Fig. 4). Mutations leading to the
absence of these transcripts in cancer libraries may have a
role in cancer establishment and its progression and may
therefore warrant further studies examining their clinical
potential.
Interestingly, when dividing genes into oncogenes, tumour
suppressors and other genes, we found marginal increases in
stop codons in oncogene-derived transcripts in cancer librar-
ies, while tumour suppressor genes showed a strong increase
in premature stop codons. We found a higher incidence of
premature stop codons among of tumour suppressor genes in
both normal-speciﬁc and cancer-common AS (Fig. 5). This
is not explained by differences in coding region length
(Supplementary Material, Figs S1 and S2). The fact that
cancer-speciﬁc oncogene transcripts have a higher functional
content compared to those normal speciﬁc suggests that, in
Figure 6. AS event frequency for normal and cancer transcripts divided into oncogene tumour suppressor and other genes. Left and right panels represent cancer-
speciﬁc and normal-speciﬁc AS events, respectively. Distributions for normal-speciﬁc AS events are the average results from 100 randomly selected samples of
equal size to the number of cancer-speciﬁc AS events. Top panels present the percentage of AS events which are present in more than one copy and or more than
one library. Bottom panels are a box plot of the average number of copies per AS event or the number of libraries where each AS event is present. Stars represent
signiﬁcant differences among groups from top panels (Chi-square test) and bottom panels (Wilcoxon test) with P , 0.05 (∗), 0.001 , P , 0.01 (∗∗) and
P , 0.001 (∗∗∗).
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may confer novel functional properties to protein products
potentially having a role in cancer cells. Given that this set
of transcripts are mostly found in single libraries, it is likely
that their functional contribution is likely to be speciﬁc to
cancers of individual patients.
Weconcludethatcancerstatesareassociatedwithanelevated
rate of aberrant transcripts particularly pronounced in tumour
suppressor genes but from which oncogenes are spared. We
therefore suggest that splicing noise should be considered
when evaluating cancer-speciﬁc splicing events as they have a
signiﬁcant higher incidence of premature stop codons. Given
that nonsense mutations affect only a minority of transcripts,
it is feasible to assume that most cancer- and normal-speciﬁc
transcripts may be transcribed into functional proteins and
maycontributesigniﬁcantlytothecancerousphenotype.Never-
theless, the fact that most cancer-speciﬁc splice variants we
identiﬁed are found as single copies in one EST library may
somewhat limit their value as wide spectrum diagnostic
probesand/ortreatmenttargets.AssessmentofglobalASsigna-
tures by gene category may be more promising. Finally, we
propose that the roles of normal speciﬁc and mutation in
common AS variants should be examined in addition to cancer-
speciﬁc transcripts; analyses of these absent AS transcripts may
further aid in the understanding of the cancer physiology.
MATERIALS AND METHODS
Data sources
Sequence and genome annotations were obtained from
Ensembl. EST sequences and library information were
downloaded from UniGene (17).
Identiﬁcation of AS events
To estimate AS events in different organisms, a novel proced-
ure was applied as follows: (i) mapping predicted genes and
ESTs to genome and grouping ESTs for each gene. Overlap-
ping and nested genes were identiﬁed and removed from
further analyses. GMAP (18) was used to align full transcripts
and high-quality ESTs to their corresponding predicted genes.
Genes with no matching transcripts were removed from
further analyses. (ii) Template building. To obtain a gene
Figure 7. Identiﬁable functional components in AS events in cancer and normal transcripts divided into oncogene, tumour suppressor and other gene-derived.
Top panel shows the percentage of AS events with at least one identiﬁable functional component (see Materials and Methods). Bottom panel shows average
number of identiﬁable functional components per AS area. In both panels, AS events were divided into groups as in Figure 3 and further subdivided into onco-
gene, tumour suppressor and other genes. Stars represent signiﬁcant differences among groups from top panels (Chi-square tests; no signiﬁcant comparisons
found) and bottom panels (Wilcoxon tests; with P , 0.01 denoted by ∗∗ and P , 0.05 denoted by ∗).
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were overlaid onto the genomic sequence. This was done as
follows: first the longest partial or full transcript available
forms the base of the template. All other mRNAs and ESTs
are then aligned to the genomic sequence and boundaries
with the previously included transcripts are revised to extend
exons or include new ones. If a transcript only encompasses
a single exon then it will be discarded. This allows identifying
any single exon which has not been previously annotated and
discarding any non-supported exons annotated in ‘predicted
gene’. (iii) Detecting AS events. We developed an algorithm
for AS event detection to compare the exon boundaries of
any transcript to its corresponding template. Discrepancies
of ,15 bp in the length were discarded. To identify AS iso-
forms, transcripts were ﬁrst sorted according to the number
of AS events they contain. Then transcripts containing identi-
cal or similar AS events were classed as redundant. Each AS
event was classiﬁed depending on whether it derives from
cancer or normal libraries. Those AS events not found in
either normal or cancer libraries were deemed cancer or
normal speciﬁc, respectively, while AS events shared in both
normal and cancer libraries were deﬁned as normal common
and cancer common, respectively.
Identiﬁcation of premature stop codons, functional
and structural protein components per AS event
As transcripts supporting the same AS event may contain pre-
mature stop-codon causing mutations, stop-codon presence
was characterized and counted on a per transcript basis.
Other features such as functional components were jointly
analysed for each splicing event. To calculate the proportion
of AS transcripts with stop codons, BLASTX (20) was run
to search for open reading frames according to protein
sequences. From the BLASTX alignment ﬁles, amino acid
sequences of AS area were extracted and stop codons were
identiﬁed and counted. To functionally characterize AS
events, we used InterProScan which contains 14 applications
for the prediction of protein domains (21), including Pfam
for the prediction of protein domains (22), SignalP 3.0 for
signal peptide predictions (23) and TMHMM (24) for the pre-
dictions of transmembrane domains. PSORT II (25) was used
to identify the likely sub-cellular localization of protein
products. Secondary protein structures were predicted by
CLC Main Workbench 5.7, which is based on extracted
protein sequences from the protein databank (http://www.
rcsb.org/pdb/).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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